Novo Nordisk A/S-BNONOF
13F holders, Q1 2026 (March 31)3holders +1
2new positions
1sold out
$154.11avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Novo Nordisk A/S-B (NONOF) in their 13F filings, up 1 from Q4 2025. 2 opened new positions and 1 sold out. The largest holders were Cygnus Capital Advisors, LLC ($12.7M), Generali Investments CEE, investicni spolecnost, a.s. ($1.1M) and Atlas Capital Advisors Inc. ($186K).
- Company
- Novo Nordisk A/S-B
- CUSIP
- K72807140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $13.7M |
| Exits | 1 | $3K |
All 13F filers, Q4 2025 → Q1 2026: 85,119 shares bought and 60 shares sold, net +85,059 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Cygnus Capital Advisors, LLC | 8.65% | New | 54,800 | $12.7M |
| Generali Investments CEE, investicni spolecnost, a.s. | 0.06% | New | 30,319 | $1.1M |
| Atlas Capital Advisors Inc. | 0.02% | No change | 5,218 | $186K |
"% of holder's portfolio" is NONOF's weight in each manager's 13F, not the share of Novo Nordisk A/S-B the manager owns.